5/30/2013

BioMerieux has obtained FDA approval for its THxID BRAF system, a polymerase chain reaction-based test used to detect certain BRAF mutations in melanoma cells. The assay is approved as a companion diagnostic test to two advanced melanoma drugs from GlaxoSmithKline, which also concurrently received FDA approval.

Related Summaries